Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Gluten/Celiac Disease Neuropathy
    ABSTRACT & COMMENTARY

    Gluten/Celiac Disease Neuropathy

    March 1, 2021
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    Separating Celiac Disease From Non-celiac Gluten Sensitivity

    Childhood Gluten Intake and Risk of Celiac Disease

    Does Gluten Cause Health Problems in Patients Without Celiac Disease?

    Related Products

    Idiopathic Phrenic Neuropathy

    Prognosticating Ulnar Neuropathy at the Elbow

    Neuropathy in Myeloma

    Keywords

    gastrointestinal

    Neuropathy

    intestinal

    gluten

    celiac

    By Michael Rubin, MD

    Professor of Clinical Neurology, Weill Cornell Medical College

    SYNOPSIS: Gluten neuropathy should be suspected in any patient who presents with a neuropathy and has a history of gastrointestinal disease. The diagnosis is made using blood serology plus intestinal mucosal biopsy.

    SOURCE: Zis P, Sarrigiannis P, Artemiadis A, et al. Gluten neuropathy: Electrophysiological progression and HLA associations. J Neurol 2021;268:199-205.

    Sensitivity to dietary gluten and related proteins in genetically predisposed persons carrying human leukocyte antigen (HLA) DR3-DQ2 and/or DR4-DQ8, results in an immune-mediated small bowel inflammatory disease, known as celiac disease or gluten-sensitive enteropathy, classically manifesting with gastrointestinal symptoms, including diarrhea, flatulence, and weight loss, but also with neuropsychiatric symptoms including peripheral neuropathy, headache, ataxia, epilepsy, depression, and anxiety. Describing the progression of gluten neuropathy (GN) over time, and the role of genetic susceptibility in its development, were the aims of this study.

    Conducted at the Sheffield Institute of Gluten Related Diseases, Sheffield, UK, this cohort study involved 45 GN patients, over a mean follow-up period of 8 ± 5 years. Inclusion criteria required patients age 18 years or older who were able to provide written consent, with serologic evidence of gluten sensitivity (antigliadin immunoglobulin G [IgG] and/or immunoglobulin A [IgA], endomysial, or transglutaminase antibodies), electrodiagnostically proven peripheral neuropathy, and absence of other potential causes of neuropathy. Normalization of circulating antigliadin IgG and/or IgA, endomysial, and/or transglutaminase antibodies was considered evidence of adherence to a strict gluten-free diet.

    All patients underwent an electrodiagnostic study at enrollment and another at least one year later. Using sequence-specific primers, HLA-DQ typing was performed using the polymerase chain reaction. Statistical analysis included Fisher’s exact test, the Mann-Whitney U test, the Chi-square test, and Yates correction as appropriate.

    Among 45 consecutive patients with GN, 73.3% were male, the mean age of onset was 56 ± 12 years, and the mean age of diagnosis was 60 ± 12 years. Numbness (36%), tingling (18%), and pain (13%) were the most common initial symptoms, with 9% presenting with weakness and/or fasciculations. Length-dependent neuropathy was seen in 75.6%, and sensory ganglionopathy in the remainder, with the former more likely to carry the DQB1*06 allele and the DQA1*01/DQB1*06 haplotype, and the latter more likely to be DQA1*02-positive rather than negative (P = 0.009).

    Nerve conduction studies showed a linear deterioration over time in the amplitudes of the radial and sural sensory nerves and tibial motor nerves, independent of age or gender. Gluten neuropathy is a late manifestation of gluten intolerance, it usually is a length-dependent neuropathy that deteriorates in a linear fashion over time, and HLA genotyping can help identify patients at risk for developing this complication.

    COMMENTARY

    Although the pathogenesis of celiac disease remains unclear, the gastrointestinal microbiome composition may play a central role. Ingestion of gluten is needed to initiate the disease, and recent evidence suggests that earlier age of disease onset may be related to the amount of gluten ingested in infancy. Abnormal permeability of the intestinal lining, perhaps a consequence of intestinal viral infection, allows entry of incompletely degraded gliadin peptides, and this is thought to be the initial event in disease pathogenesis.

    Gliadin appears to have a direct toxic effect on the mucosa, resulting in immediate modification, within an hour, of the mucosal microenvironment, followed by involvement of T cells and full-blown mucosal changes characteristic of the disease. Although serologic markers are highly specific for the diagnosis, confirmation in adults still requires duodenal biopsies, although for the pediatric population, a “biopsy avoidance strategy” is afoot.

    Therapeutic trials currently in progress offer promising nondietary treatment for celiac patients, including latiglutenase, an orally administered mixture of two enzymes that degrade gluten proteins.

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Neurology Alert

    View PDF
    Neurology Alert (Vol. 40, No. 7) - March 2021
    March 1, 2021

    Table Of Contents

    Long-Term Treatment of Hereditary Amyloid Neuropathy with Patisiran

    Gluten/Celiac Disease Neuropathy

    Efficacy and Safety of Cannabidiol in Treatment of Focal Seizures Associated with Tuberous Sclerosis Complex

    Spontaneous Intracranial Hypotension Syndrome

    Stem Cell Transplantation for MS Treatment

    Begin Test

    Buy this Issue/Course

    Financial Disclosure:

    Dr. Rubin (author) reports he is a consultant for Merck Sharpe & Dohme Corp. All of the relevant financial relationships listed for this individual has been mitigated. None of the remaining authors or planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421 x 2

    International +1-404-262-5476 x 2

    Accounts Receivable

    1-800-688-2421 x 3
    ReliasMedia_AR@reliasmedia.com

    Sales

    1-800-688-2421 x 1

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2022 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing